Heart failure with preserved ejection fraction (HFpEF) affects half of all patients with heart
failure worldwide, is increasing in prevalence, confers substantial morbidity and mortality …

Diffuse myocardial fibrosis resulting from the excessive deposition of collagen fibres through
the entire myocardium is encountered in a number of chronic cardiac diseases. This lesion …

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …

The incidence of heart failure is primarily flat or declining for a presumably reflecting better
management of cardiovascular diseases, but that of heart failure with preserved ejection …

Hypertension constitutes a major risk factor for heart failure with preserved ejection fraction
(HFpEF). HFpEF is a prevalent clinical syndrome with increased cardiovascular morbidity …

The NLRP3 inflammasome has been implicated in the development and progression of
heart failure. The aim of this study was to determine the safety of an oral inhibitor of the …

Background Type 2 diabetes and prediabetes are risk factors for heart failure and adverse
heart failure outcomes. The Dapagliflozin Evaluation to Improve the Lives of Patients with …

Oxidative stress (OS) is mediated by reactive oxygen species (ROS), which in
cardiovascular and other disease states, damage DNA, lipids, proteins, other cellular and …

Background Empagliflozin reduces cardiovascular death (CVD) or heart failure (HF)
hospitalization (HFH) in patients with HF and preserved ejection fraction. Treatment effects …

Background About half of heart failure (HF) patients, while having preserved left ventricular
function, suffer from diastolic dysfunction (so‐called HFpEF). No specific therapeutics are …